Steven Deeks, MD | UCSF-Bay Area Center ...

Dr. Steven J Deeks, MD

Claim this profile

San Francisco General Hospital

Studies Human Immunodeficiency Virus Infection
Studies HIV Infection
12 reported clinical trials
15 drugs studied

Affiliated Hospitals

Image of trial facility.
San Francisco General Hospital
Image of trial facility.
University Of California San Francisco

Clinical Trials Steven J Deeks, MD is currently running

Image of trial facility.

Leukapheresis

for HIV/AIDS

Despite the dramatic improvements that have resulted from combination antiretroviral treatment, long-term efficacy, toxicity, cost, and the requirements for life-long adherence remain as formidable challenges. Also, there is emerging consensus that persistent HIV-associated disease occurs during long-term highly active antiretroviral therapy (HAART). This disease may be due to either direct drug-toxicity and/or persistent viral replication/production and/or persistent HIV-associated inflammation. Hence, strategies aimed at achieving complete viral eradication may be needed in order to fully restore health among HIV infected individuals. Even if complete eradication proves impossible-as most believe to be the case-a less rigorous but still desirable outcome might be achieving durable control of virus in the absence of therapy. That a "functional" cure is possible is well illustrated by those rare individuals who are able to durably control replication competent virus in the absence of therapy ("elite" controllers). A more complete understanding of the relationship between inflammation and viral persistence is necessary before more rationale studies of HIV eradication can be designed. Also, a well validated high through-put virologic assay needs to be developed that can estimate the size of the latent reservoir. Since the level of replication competent virus in long-term treated patients (and in elite controllers) is very small (\< 1% of CD4 cells harbor HIV), large numbers of CD4+ T cells most be obtained from study participants in order to routinely isolate and quantify virus persistence.
Recruiting1 award N/A4 criteria
Image of trial facility.

PET-MR Imaging with [18F]F-AraG

for HIV Infection

This is a single center exploratory imaging study involving one intravenous microdose of \[18F\]F-AraG followed by whole-body positron emission tomography-magnetic resonance (PET-MR) imaging in HIV infected individuals to determine the anatomical distribution of the PET tracer. Participants will be enrolled if they were treated during early or late HIV infection. In addition, individuals not on antiretroviral therapy (ART) or with HIV-1 plasma RNA levels \>5,000 copies/mL will be enrolled. Up to 30 participants will be enrolled with HIV.
Recruiting1 award Phase 2

More about Steven J Deeks, MD

Clinical Trial Related4 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Steven J Deeks, MD has experience with
  • Placebo
  • Cyclophosphamide
  • LVgp120duoCAR-T Cells, High Dose
  • LVgp120duoCAR-T Cells, Low Dose
  • Treatment Interruption Arm
  • [18F]F-AraG

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Steven J Deeks, MD specialize in?
Is Steven J Deeks, MD currently recruiting for clinical trials?
Are there any treatments that Steven J Deeks, MD has studied deeply?
What is the best way to schedule an appointment with Steven J Deeks, MD?
What is the office address of Steven J Deeks, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security